As a Senior Clinical Scientist at VeraSci, Dr. Karas provides scientific expertise and oversight for clinical trials within the CNS indications. Dr. Karas has served as the clinical lead for global phase II and phase III clinical trials in several CNS indications including Alzheimer’s disease, essential tremor, mild cognitive impairment (MCI), Parkinson’s disease, and traumatic brain injury (TBI). Additionally, Dr. Karas has provided oversight to data reviewers on several data quality surveillance programs and reviewed hundreds of cognitive and clinical assessments. She is passionate about using the data from these surveillance programs to tailor rater training and certification programs and build out eCOA platforms that assist raters in adhering protocol standards.
Before Dr. Karas’ full-time transition to the clinical trial industry, she worked at outpatient and clinical research centers ranging from integrative health to end-of-life transitions to memory clinics.